We have found that 6 of 31 independently derived human small-cell lung cancer (SCLC) cell lines have 5-to 170-fold amplified N-myc gene sequences, The amplification is seen with probes from two separate exons of N-myc, which are homologous to either the second or the third exon of the c-myc gene. Amplified N-myc sequences were found in a tumor cell line started prior to chemotherapy, in SCLC tumor samples harvested directly from tumor metastases at autopsy, and from a resected primary lung cancer. Several N-myc-amplified tumor cell lines also exhibited N-myc hybridizing fragments not in the germ-line position. In one patient's tumor, an additional amplified N-myc DNA fragment was observed and this fragment was heterogenously distributed in liver metastases. In contrast to SCLC with neuroendocrine properties, no nonsmall-cell lung cancer lines examined were found to have N-myc amplification. Fragents encoding two N-myc exons also detect increased amounts of a 3.1-kilobase N-myc mRNA in N-mycamplified SCLC lines and in one cell line that does not show N-myc gene amplification. Both DNA and RNA hybridization experiments show that in any one SCLC cell line, only one mycwrelated gene is amplified and expressed. We conclude that N-myc amplification is both common and potentially significant in the tumorigenesis or tumor progression of SCLC.
Gene amplification represents an important adaptive mechanism allowing selective increased expression of genes whose products are needed by the cell (1, 2) . Thus, the finding of amplification and expression of protooncogenes in tumor cells suggests an important role for the protooncogene product in the cellular and clinical biology of these tumors (3) (4) (5) (6) (7) (8) (9) . We reported previously that eight independent human small-cell lung cancer (SCLC) lines have stable amplification and increased expression or deregulated expression alone of the c-myc gene (6, 10) . Recent studies have shown increased expression with or without amplification of a c-myc-related gene, N-myc, in tumors of neural origin, including neuroblastoma and retinoblastoma (7) (8) (9) . In this paper, we show that six independently derived SCLC lines that express neuroendocrine properties (10) (11) (12) also have amplified Nmyc sequences and increased levels of N-myc expression compared to non-N-myc-amplified cell lines. In addition, tumor tissues harvested directly from three of these SCLC patients, including one from an untreated primary tumor, also show amplification of the N-myc gene. These results demonstrate that either c-myc or N-myc has been found amplified in 14 of 31 different SCLC lines. This suggests that expression with or without amplification of a myc-related gene may play a prominent role in the biology of SCLC.
MATERIALS AND METHODS
Cloned DNA Fragments. Specific cloned DNA fragments purified from vector sequences were used as probes and are described in the various figure legends. The human c-myc plasmids were a gift of Philip Leder and were both obtained from a 12.7-kilobase (kb) EcoRI fragment isolated and cloned from human lymphocyte DNA (13) . The plasmid pNb-1 containing a human N-myc fragment isolated from a human neuroblastoma cell line (7) was provided by Manfred Schwab and J. Michael Bishop. A plasmid containing a human oxytocin (OT) gene fragment was derived as described (14) .
Additional specific N-myc fragments were prepared in our laboratory from a genomic library bacteriophage clone, Ch N-myc 4. The clone was isolated from a partial Mbo I human placenta library in Ch28 (provided by Philip Leder) (15) using Nb-i as a probe. Specific fragments in the genomic clone that show homology to the second c-myc exon or Nb-i fragment (1.0-kb EcoRI/BamHI placental fragment) and the third c-myc exon (2.2-kb Bgl TI/EcoRI placental fragment) were identified by hybridization. Fragments containing these genes were subcloned into pJB327 (14) (see Fig. 3 schematic map).
Cell Lines and Tumor Specimens. The lung cancer cell lines established, grown, and characterized in our laboratory (10, 11) include the following National Cancer Institute (NCI)  SCLC lines: H69, H82, H187, H209, H249, H372, H378,  N417, H446, H510, H526, N592 , and H689; and NCI nonsmall-cell lung cancer (NSCLC) lines H125 and H157. The human tumor specimens were obtained as part of National Institutes of Health approved clinical research protocols. The neuroblastoma cell line SMS-KCNR (16, 17) was kindly provided by Patrick Reynolds.
DNA and RNA Blot Hybridization. DNA from cell lines was prepared from lysed cells (18) or from guanidine thiocyanate/cesium chloride gradients (19) and were processed as described (18) . Solid tissues were first pulverized in liquid nitrogen in a blender before DNA extraction (20) . DNA (12 ,ug) was digested with EcoRI, electrophoresed on a 0.8% agarose gel, denatured, and transferred to nitrocellulose essentially as described by Southern (21) . Hybridization was performed with 10% dextran sulfate and 40% formamide (22) with 32P-labeled restriction fragment probe, as indicated in various figures, and washed at 52°C in 0.1X SSC (1x SSC = 0.15 M NaCl/0.015 M Na citrate)/0.1% NaDodSO4 as described (23 were also determined from serial dilutions of N-myc-amplifled DNA and these bands were also cut out and counted (Fig.  lb) . Both approaches yielded similar values.
Total cellular RNA was prepared by guanidine thiocyanate/cesium chloride gradient centrifugation (19) and then poly(A)+ RNA was selected (24) . Poly(A)+ RNA (2.5 or 5.0 jig) was denatured and electrophoresed on a 1% or 1.4%
agarose formaldehyde gel according to Lehrach et al. (25) , modified by using 0.22 M formaldehyde in the gel, at 160 V for 4-6 hr. Transfer was as described (26) , hybridization was carried out at 420C in 10% dextran sulfate/50% formamide/4x SSC, and washing was at 650C in 0.1x SSC/0.1% NaDodSO4.
RESULTS
Detection of a c-myc-Related DNA in SCLC. While searching for c-myc amplification in SCLC, we also observed that several SCLC lines contained a faint 2.0-kb EcoRI fragment that hybridized to a human second exon c-myc probe (Fig.  la) . Concurrently, workers in two laboratories reported amplification of a 2.0-kb EcoRI c-myc-related sequence in human neuroblastomas (7, 27) . This sequence, named Nmyc, was shown to contain limited homology to the second exon of c-myc (7) . Its human germ-line location is on chromosome 2 (27, 28) , a different location from the germline c-myc gene on chromosome 8 (23) . We speculated that this 2.0-kb EcoRI fragment cross-hybridizing with human c-myc might represent N-myc gene amplification in SCLC DNA.
Several SCLC Cell Lines Contain Amplified N-myc DNA Sequences. To confirm this, a human N-myc probe (Nb-1) (7) was used in Southern blotting experiments against EcoRIdigested genomic DNA from SCLC and NSCLC cell lines. Five SCLC lines (H69, H249, H372, H526, H689) were found to be markedly amplified for the 2.0-kb N-myc DNA when compared to other lung cancer cell line DNAs (Fig. lb) . The degree of N-myc amplification was determined and we found the following: H69 amplified 85-fold; H249 amplified 150- fold; H372 amplified 35-fold; H526 amplified 115-fold (5.5-kb band) and 135-fold (2.0-kb band); and H689 amplified 170-fold. One DNA from cell line H526 showed equal amplification of another 5.5-kb N-myc-hybridizing EcoRI fragment. This amplified fragment could be the result of an N-myc rearrangement, the loss of an EcoRI restriction site during amplification, amplification of an N-myc polymorphism, or the presence of a new myc gene related to N-myc. While most of the cell lines derived from tumor specimens of patients who relapsed after chemotherapy, H526 was started from a tumor sample biopsy prior to chemotherapy (11) . None ofthe SCLC lines with N-myc amplification had c-myc amplification using the second exon c-myc probe (see Fig. la for examples). Likewise, no SCLC cell lines previously shown to be amplified for the c-myc gene (H60, H82, H211, H360, N390, N417, H446, and H524) (6, 10) In patient H526, it is interesting to note that the 5.5-kb EcoRI amplified N-myc-related species found in the cell line (established from a bone marrow tumor biopsy sample) was present in only one of the liver metastases, while all tumor tissues from this patient contained the 2.0-kb EcoRI-amplifled N-myc fragment typically seen. On long exposures, no 5.5-kb fragment was seen in normal tissue DNA from this patient, arguing against the idea that this fragment is an inherited restriction fragment length polymorphism of the N-myc gene.
We also tested primary lung tumor tissue from an untreated SCLC patient from which cell line H720 has been established (Fig. 2d) . As a single copy gene control in these experiments, the human oxytocin gene (01) was included in the hybridization reaction (24) . Southern blot analyses demonstrate that the 2.0-kb EcoRI N-myc fragment is amplified (5-fold) in the primary lung tumor tissue. In H720, we also noted additional fragments (Fig. 2d) . DNA prepared from the cell line H720 also reveals N-myc DNA amplification (data not shown). This finding shows that N-myc amplification can take place in the patient prior to metastasis.
An Amplified N-myc Domain Related to the Third Exon of the c-myc Gene Is Present in SCLC. To extend our N-myc amplification studies, we used the Nb-1 N-myc fragment as a probe and isolated a human placenta genomic DNA bacteriophage clone (Ch N-myc 4). (See Materials and Methods and Fig. 3.) A region homologous to the third c-myc exon in Ch N-myc 4 was identified in a 2.2-kb Bgl II/EcoRI fragment located "-2.8 kb 3' to the fragment equivalent to Nb-1 (Fig. 3, solid bar) . This fragment lies in the same region reported earlier by Michitsch et al. (30) as homologous to the third c-myc exon and amplified in human neuroblastomas, and in the same region as a domain identified by Schwab et al. within which the 3' end of the N-myc gene must be contained (31) . The restriction map surrounding this placental Bgl II/EcoRI fragment is identical to that described by Schwab et al. (31) . We wished to determine whether this region 3' to Nb-1 was also amplified and expressed in SCLC. As predicted from the partial restriction map, this fragment did detect a 4.2-kb EcoRI fragment in genomic digests of all SCLC cell line DNAs (Fig. 3) . This fragment is only amplified in those SCLC DNAs that contain the 2.0-kb EcoRI-amplified N-myc sequence. Note that cell line H187 (which we later show expresses N-myc), H446 (amplified for c-myc) (6), and H510 (amplified for L-myc) (29) do not show N-myc amplification.
N-myc DNA Ampliflication Is Stable Over Time in Cell
Culture. Loss of amplified sequences [e.g., the dihydrofolate reductase (dhfr) gene] can occur when selection pressure is released (1, 2). We have previously reported that SCLC tumor line H249 lost amplified dhfr gene sequences when grown in cell culture in the absence of methotrexate, which had apparently selected for the amplified dhfr sequences in the patient (32) . However, no apparent change in the amount of N-myc gene amplification was noted in cell lines H249 and H526 (Fig. 2a) after continuous growth in culture for >30 and >15 weeks (=70 and -50 population doublings), respectively.
We were also able to compare the stability of N-myc amplification in the same tumor specimen passaged directly from the patient into tissue culture (H249) or first injected into a nude mouse to form a xenograft (N592). We found that Proc. Natl. Acad Sci. USA 83 (1986) Wl WIN`, N-myc was amplified in both H249 and N592 but to an even greater degree in the N592 xenograft line than in the H249 cultured cell line (Fig. 3) . We were also able to show that seven independent clones, four derived from H249 and three from H526, all contained the same level of amplified N-myc sequences (data not shown). All H249 clones were found to contain approximately equal amounts of the 2.0-kb EcoRI fragment, while H526 clones had equal amounts of both 5.5-and 2.0-kb EcoRI N-myc hybridizing fragments. This suggests that most clonogenic cells in these two lines contain stably amplified N-myc sequences and, in H526, that both amplified fragments are present in the same cell.
Detection of N-myc Transcripts in N-myc DNA-Amplified SCLC Cell Lines. N-myc gene expression was examined in SCLC cell lines and in one neuroblastoma cell line known to express N-myc (17) using as probes both Nb-i (with homology to the second exon of c-myc; Fig. 4a ) and the 3' Bgl II/EcoRI placental N-myc fragment (having homology to the third exon of c-myc; Fig. 4b ). The neuroblastoma cell line (KCNR) and SCLC cell lines with N-myc amplification (H69, H249, H592, and H526) contain a 3.1-kb N-myc transcript. The 3.1-kb size of the predominant N-myc transcript was determined by using both human (28S and 18S) and Escherichia coli (23S and 16S) ribosomal RNAs as standards. This value coincides with that observed for neuroblastoma transcripts (3.2 kb) by Kohl et al. (27) , but it differs from the 4.0-kb size reported by Schwab et al. (33) . Several larger transcripts in those lines expressing N-myc are seen, includ- (7) and (b) the 2.2-kb Bgi II/EcoRI 3' placental N-myc probe. Open bar labeled Nb-1 indicates probe used in a; solid bar indicates probe used in b; heavy vertical lines show regions of homology between c-myc and N-myc DNA sequences (7) . B, BamHI site; Bg, Bgl II site; R, EcoRI site; X, Xho I site; P, Pvu II site. The 3.1-and 4.7-kb positions indicate N-myc-specific transcripts determined using human (28S and 18S) and E. coli (23S and 16S) ribosomal RNAs as markers. The six lanes on the right side of both a and b show no detectable N-myc hybridization (lines H125, H82, N417, H209, H378, H510), contained 5 t&g of poly(A)+ RNA, and were exposed three times as long (72 hr). The N-myc-expressing cell lines (Left) (KCNR, H187, H69, H249, N592, H526) contained 2.5 ,ug of poly(A)+ RNA and were exposed 24 hr. ing one at 4.7 kb, which probably represent N-myc precursor RNAs (33) . It is of interest to note that both the Nb-i probe (Fig. 4a ) and the 3' Bgl II/EcoRI placental N-myc fragment probe yield identical results, confirming that this 3' N-myc fragment does contain an exon of the N-myc gene. The independently maintained nude mouse heterotransplant cell line N592 started from the same original tumor, as H249 shows more N-myc expression than H249 mirroring the DNA amplification results. One SCLC cell line (H187), not amplified for the N-myc gene sequence, also expresses a 3.1-kb N-myc RNA transcript. This recalls earlier observations that some neuroblastoma (33) and retinoblastoma (9) cell lines, not amplified for N-myc, express detectable N-myc transcripts. In addition, H526 RNA also contains a 1.8-kb N-myc hybridizing transcript (Fig. 4a) , which could result from transcription of the 5.5-kb EcoRI N-myc hybridizing DNA fragment (see Fig. lb) . In marked contrast, no N-myc expression was observed in a NSCLC cell line (H125), two cell lines amplified and expressing the c-myc gene (H82 and N417), and three SCLC cell lines with expression of the newly described L-myc gene (H209, H378, and H510) (29) . c-myc Genes Are Not Coexpressed in N-myc-Expressing SCLC Cell Lines. Fig. 4 shows that c-myc-expressing cell lines (H82, N417) do not express N-myc mRNA. We then examined the SCLC cell lines that expressed increased amounts of N-myc for c-myc expression by using a third exon c-myc probe (Fig. 5) No evidence of c-myc transcription was seen in the N-myc-amplified and -expressing cell lines (H69, H249, H372, and H526), while SCLC cell lines known to be amplified and expressing the c-myc gene sequence had abundant c-myc mRNA (H82 and N417). In the SCLC cell lines examined to date, we have found no cell lines to have the c-myc, N-myc, or L-myc genes simultaneously amplified or expressed. DISCUSSION N-myc amplification and/or expression is observed thus far in three human tumors, all of which have neural or neuroendocrine properties: neuroblastoma (7, 8) , retinoblastoma neuroblastoma is associated with a more advanced clinical stage (4). In neuroblastoma (7, 8, 30) and SCLC, the amplification is a somatic event present in tumor but not in normal tissue from the same patient. An expressed N-myc gene can complement mutant ras genes in the tumorigenic conversion of rat embryo fibroblasts (31, 34) , suggesting that this gene can provide an important function in the establishment and maintenance of transformation. In addition, we have shown here that: (i) amplification of the N-myc gene can occur in both primary and metastatic lung tumors; (ii) amplification is maintained stably over many passages in cell culture, while amplified genes for DHFR in the same tumor line were lost (32); and (iii) when passaged as a nude mouse xenograft, the amplification and expression of N-myc is retained and may increase. All of these facts provide circumstantial evidence for an important role for N-myc in the growth of these human tumors.
Previously, we have shown that every example of c-myc amplification in SCLC occurred in a morphologic and biochemical variant subclass of SCLC, which is characterized by a distinct large cell morphology, shorter doubling time, and higher cloning efficiency in vitro, as well as greatly reduced or absent expression of the neuroendocrine enzyme marker, L-dopa decarboxylase (10, 11) . In contrast, N-myc amplification is found in both classic (H69, H249) and variant (H372, H526) types of SCLC. The doubling times (36-126 hr) and agarose colony-forming efficiencies (0.6-12%) measured in vitro of the N-myc-amplified lines overlap the values observed in SCLC with or without c-myc amplification (10, 11) . Thus, further studies are needed to define the role of the N-myc gene in regulating the growth and differentiation of these cells.
We have found a SCLC cell line (H187) that expresses N-myc mRNA without amplification, a feature also seen in some neuroblastomas and retinoblastomas (7, 9) . The association of N-myc gene expression with neural and neuroendocrine tumors might reflect a specific requirement for the N-myc gene product during the normal embryologic development of these cell types. In this regard, in situ hybridization studies show increased N-myc expression in the undifferentiated neuroblast component of neuroblastomas (31) , while induction of neuroblastomas to differentiate using retinoic acid is associated with decreased levels of N-myc expression (17) .
In addition to expression during normal development, the c-myc gene expression is altered by translocation (23) , amplification, and probably other as yet unexplained mechanisms. Similarly, while N-myc amplification was associated with increased N-myc expression, other mechanisms of N-myc gene activation must also be considered. One N-mycamplified SCLC (H526) exhibits an amplified N-myc restriction fragment heterogeneously distributed in the patient's tumor metastases, while additional N-myc hybridizing fragments were seen in other lines (e.g., H249, H720). These hybridizing restriction fragments could represent rearranged N-myc genes or amplification of an N-myc-related gene.
Recently, we have identified another myc family member (which we have called L-myc, since it was first detected in a lung cancer) in human SCLC (29) . L-myc also shares homology with both N-myc and the second exon of the c-myc gene. Using an L-myc-specific probe, five SCLCs with L-myc amplification have been found (29) . None of these SCLC lines expresses or is amplified for the N-myc gene (H378 and H510; Figs. 1, 3, and 4) or the c-myc gene (H378; Fig. 5 ). The results presented here, combined with our prior studies, give a total of 21/31 SCLC lines amplified and/or expressing one ofthe myc family ofgenes (nine c-myc, seven N-myc, and five L-myc). In SCLC, we have seen expression of only one of these myc family members in any individual tumor cell line. These results raise the possibility that deregulation of a myc-like gene is a common and perhaps necessary occurrence in some SCLC tumors.
